Glisen VM 1 Tablet SR is a combination oral antidiabetic medication containing Glimepiride (1mg), Metformin (500mg), and Voglibose (0.2mg), formulated to improve glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves insulin sensitivity in peripheral tissues, contributing to better glucose uptake and utilization. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption in the intestines, leading to reduced postprandial hyperglycemia. The sustained-release (SR) formulation ensures a gradual release of active ingredients, promoting consistent plasma concentrations and improved patient compliance by reducing dosing frequency. Glisen VM 1 Tablet SR is indicated as adjunctive therapy to diet and exercise for adults inadequately controlled on monotherapy or dual therapy with these agents. It is essential to monitor blood glucose levels regularly and adjust dosage based on therapeutic response and tolerability. Caution is advised in patients with renal or hepatic impairment, and potential adverse effects include hypoglycemia, gastrointestinal disturbances, and lactic acidosis. This combination offers a comprehensive approach to managing hyperglycemia by targeting multiple pathophysiological defects in type 2 diabetes.